NCT07004816View on ClinicalTrials.gov

The Mutation Profile and Prognosis in AML With IDH1/2 Mutation

CompletedOBSERVATIONAL
Enrollment

1,015

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

March 24, 2020

Study Completion Date

March 24, 2020

Conditions
AML
Interventions
OTHER

Uncover mutation profiles

Uncover mutation profiles

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT07004816 - The Mutation Profile and Prognosis in AML With IDH1/2 Mutation | Biotech Hunter | Biotech Hunter